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162 CDK = cyclin-dependant kinase; KIP = kinase inhibitor protein; PKB = protein kinase B; PI3K = phosphatidyl inositol 3′-kinase.
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Introduction
Three papers published concurrently in the October issue
of Nature Medicine have demonstrated new links between
mitogenic cytokine signalling and the cell cycle inhibitor
p27KIP1, and have elucidated how this link may contribute
to breast cancer patient prognosis [1–3].
Cell cycle control occurs through cyclin binding to the
cyclin-dependent kinases (CDKs) that stimulate G1 pro-
gression [4]. p27KIP1 is a member of the kinase inhibitor
protein (KIP) family that inhibit cell cycle progression by
binding to cyclin-CDK complexes [5]. In cancers where
protein kinase B (PKB)/Akt is constitutively activated by
upstream oncogenes, Akt decreases p27KIP1 by increas-
ing proteolysis and reducing transcription [6].
These three articles describe a third way in which Akt
resists G1 arrest, namely by a p27KIP1 phosphorylation
that impairs nuclear import and prevents its inhibition of
cyclin-CDK complexes. The authors of these studies con-
clude that exclusion of p27KIP1 from the nucleus leads to a
poor patient outcome in breast cancer [1-3].
p27KIP1 phosphorylation leads to cytoplasmic
localisation
Wild type and constitutively active Akt were both shown to
phosphorylate p27KIP1 at threonine157, leading to cyto-
plasmic localisation of p27KIP1. Blockade of Akt activation
by the phosphatidyl inositol 3′-kinase (PI3K) inhibitor
LY294002, or transfection with the mutant p27KIP1-
T157A, led to nuclear p27KIP1 localisation. Constitutively
active Akt prevented wild type p27KIP1, but not p27KIP1-
T157A, from causing G1 arrest.
In two of the studies it was reported that approximately
40% of primary breast tumours displayed cytoplasmic
p27KIP1 staining [1,3]. The presence of cytoplasmic
p27KIP1 in human breast cancers was highly correlated
with Akt activation. The best prognostic subgroup of
breast tumours had strong, exclusively nuclear p27KIP1
staining, while cancers with lower expression levels, but
cytoplasmic localisation, had the worst survival rates.
The data indicate that p27KIP1 normally acts as a tumour
suppressor protein, but that the oncogenic activation of
Akt leads to mislocation of p27KIP1 to the cytoplasm where
it is unable to inhibit cell cycle proteins. The study indi-
cates that cytoplasmic location of p27KIP1 in breast
tumours is a prognostic indicator and that the Akt pathway
may be a good target for anti-cancer therapy.
Conclusion
p27KIP1 is an inhibitor of cell cycle progression that is
rarely mutated or silenced in cancers. The Nature Medi-
cine articles demonstrate that p27KIP1 depends on a
nuclear location to perform its cell cycle inhibitory function
and that Akt phosphorylates p27KIP1 leading to its mislo-
calisation in the cytoplasm [1–3].
Akt lies downstream of PI3K and the growth factor recep-
tors epidermal growth factor receptor (EGFR) and ErbB2,
which act as oncogenes in numerous cancers [7]. This
means that Akt is commonly activated in many forms of
cancer [8]. All three of these studies confirm that the
action of Akt on p27KIP1 localisation appears crucial to
breast tumour progression [1–3]. There is evidence that
Akt can also exclude nuclear presence of another cell
cycle inhibitor, p21CIP1 [9]. It will be interesting to see
whether the cellular location of p21CIP1 will add to the
prognostic information given by p27KIP1 in cancers.
Finally, the articles suggest new therapeutic opportunities
in targeting Akt or the p27KIP1 phosphorylation site to relo-
cate p27KIP1 to the nucleus and improve the long-term
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prognosis of breast cancer patients in whom this impor-
tant cell cycle regulator is mislocated.
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